Core Viewpoint - Veracyte, Inc. has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer to enhance its global product development strategy in cancer diagnostics [1][3] Group 1: Leadership Appointment - Kevin Haas will join Veracyte on March 24, 2026, in a newly created role focused on overseeing end-to-end product development, including diagnostic assay development, software, and bioinformatics [1][2] - Dr. Haas has over 15 years of experience in the life sciences industry, previously serving as Chief Technology Officer at Myriad Genetics, where he led the development of precision medicine platforms [3][4] Group 2: Product Development Strategy - The expansion of Veracyte's pipeline into whole-genome minimal residual disease (MRD) and multiomics applications necessitates integrated capabilities across assays, software, AI, and next-generation informatics [2] - Dr. Haas will lead efforts to deliver high-quality laboratory-developed tests (LDTs) and global in vitro diagnostic (IVD) products, aiming to accelerate innovation and support the company's global portfolio [2][3] Group 3: Company Vision and Goals - Veracyte aims to transform cancer care by providing clinicians with high-value insights for diagnosing and treating cancer, supported by a robust diagnostics platform [5][6] - The company emphasizes the importance of genomic and clinical data, bioinformatics, and AI capabilities in driving innovation and pipeline development [5][6]

Summary of Veracyte's Conference Call Company Overview - **Company**: Veracyte - **Industry**: Molecular diagnostics, specifically focused on cancer diagnostics - **Mission**: Enhance understanding of cancer and improve treatment through advanced molecular diagnostics, aiming to reach patients globally [2][3] Core Business and Financial Performance - **Revenue**: Achieved $517 million in 2025, with an 18% growth in testing revenue [5] - **Adjusted EBITDA Margin**: Exceeded 27% in 2025, surpassing the 25% target set for the year [6][26] - **Patient Reach**: Over 800,000 patients served to date, with expectations to serve the 1 millionth patient in 2026 [6][28] - **Growth Drivers**: Core business growth from Decipher and Afirma expected to support double-digit revenue growth in the foreseeable future [18] Product Portfolio Decipher Test - **Focus**: Prostate cancer prognosis and prediction, providing genomic insights to guide treatment decisions [7] - **Market Penetration**: Estimated at 33% as of the end of 2025, with significant growth potential [9] - **Volume Growth**: Achieved over 20% volume growth for 15 consecutive quarters, with a 3-year revenue CAGR of over 37% [9][10] - **Clinical Evidence**: Supported by over 100 publications, recognized in NCCN guidelines [10] Afirma Test - **Focus**: Thyroid nodule diagnosis, helping patients avoid unnecessary surgeries [15] - **Market Penetration**: Currently 38% penetrated into the Bethesda III to VI category [15] - **Volume Growth**: Experienced 11% volume growth in 2025, driven by new account wins and increased utilization [16] Upcoming Products - **TrueMRD**: Launching in 2026 for muscle invasive bladder cancer, leveraging the Decipher brand [18][22] - **Prosigna**: Expected launch in mid-2026, targeting breast cancer patients with significant market opportunity [19][20] Strategic Initiatives - **Data-Driven Approach**: Emphasizes generating more data to enhance clinical utility and adoption of tests [3][21] - **Digital Pathology and AI**: Exploring integration with molecular diagnostics, focusing on generating robust clinical evidence before commercialization [39] - **Geographic Expansion**: Plans to introduce tests like Prosigna and Decipher in Europe, addressing significant patient populations [23][24] Market Challenges and Opportunities - **Prostate Cancer**: Approximately 334,000 patients diagnosed annually in the U.S., with a growing clinical challenge [8] - **Bladder Cancer**: Strong momentum with Decipher Bladder, integrating research to guide future treatment [10][11] - **Lung Cancer**: Developing Percepta nasal swab to address early risk stratification in lung cancer patients [25] Key Takeaways - **Durability of Growth**: Confidence in sustaining growth in core business and pipeline products [40] - **Financial Strength**: Unique financial profile with strong cash generation and profitability [41] - **Underappreciated Aspects**: Core business growth, pipeline potential, and financial stability are key areas that may not be fully recognized by investors [41]

Revenue Dependence and Reimbursement - A significant portion of the company's revenue is dependent on a few payers, including Medicare and UnitedHealthcare Group, which may fluctuate and impact overall revenue [170]. - Medicare reimbursement rates for tests like Decipher Prostate and Afirma GSC are critical, with Decipher Prostate's reimbursement rate set at $3,873 and Afirma GSC at $3,600 [176]. - The company has contracts with a limited number of commercial payers for its prostate tests, and many commercial payers do not provide reimbursement or offer limited coverage [172]. - The new Local Coverage Determination (LCD) for "Gene Expression Profile Tests" is expected to enhance coverage for Decipher Prostate starting from October 18, 2024 [172]. - The company anticipates ongoing pressure from payers to limit test utilization and may face challenges due to increased patient cost-sharing and prior authorization requirements [187]. - Changes in reimbursement policies or payment rates from payers could adversely affect the company's revenue and financial condition [175]. - Medicare payments to providers, including clinical laboratories, are subject to a reduction of up to 2% per fiscal year from April 1, 2013, until 2032, with temporary suspensions during specific periods [213]. - California's Department of Health Care Services updated its reimbursement methodology for clinical laboratories in 2023, impacting Medicaid reimbursement rates [214]. - Future healthcare initiatives and regulations may lead to decreased revenue and lower reimbursement rates for tests, adversely affecting the company's financial condition [215]. - The No Surprises Act, effective January 1, 2022, may limit the prices charged for testing services, impacting revenue [221]. Regulatory Compliance and Risks - The company must maintain compliance with federal and state licensing requirements to avoid disruptions in testing services, which are essential for revenue generation [188]. - The FDA's enforcement discretion policy for laboratory developed tests (LDTs) may change, potentially subjecting existing tests to extensive regulatory requirements [231]. - Regulatory compliance failures could result in enforcement actions, adversely affecting the company's operations and financial condition [235]. - The company must comply with numerous regulations, including HIPAA and Medicare billing requirements, which can be costly and time-consuming [285]. - The company is subject to ongoing inspections and must comply with ISO standards and FDA regulations, which could lead to operational challenges if not adhered to [257]. - The IVDR has introduced a new classification system for companion diagnostics, requiring conformity assessments by notified bodies [255]. - The company faces significant competition in the breast cancer diagnostics market, primarily from Exact Sciences Corporation, which holds a substantial majority of the market share [262]. - The company is dependent on third-party technology providers to maintain compliance with regulatory standards, which is essential for the commercialization of its diagnostic products [256]. Strategic Transactions and Acquisitions - The company may engage in strategic transactions that could impact its business operations and financial resources [190]. - The company completed the C2i Acquisition in Q1 2024 to expand its role across the cancer continuum [195]. - On August 1, 2025, the company divested the contract manufacturing portion of its French subsidiary, Veracyte SAS, to Helio Diagnostics SAS [191]. - The company acquired C2i, an oncology diagnostics company based in Tel Aviv, Israel, in 2024, enhancing its international presence and capabilities [293]. Supply Chain and Operational Risks - The company relies on sole suppliers for critical reagents and materials, which poses risks to revenue generation if these suppliers fail to deliver [200]. - The company has experienced supply chain disruptions but has not yet faced delays in returning test results [206]. - Future growth will require the company to scale testing capacity and enhance internal quality assurance programs [208]. - The company’s ability to forecast accurately and plan production capacities is crucial for meeting customer demand [210]. - The company must manage inventory effectively to avoid adverse impacts on long-term growth prospects [199]. - Quality issues in manufacturing IVD test kits may arise as the company scales up production to meet demand, potentially leading to liabilities [299]. - The company faces risks related to the potential inoperability of its laboratories and equipment, which could lead to significant delays in testing services and loss of customers [368]. Financial Performance and Taxation - As of December 31, 2025, the company had net operating loss carryforwards (NOL) of approximately $561.9 million for federal tax purposes, with $57.5 million set to expire in 2036 [348]. - The company also reported state NOL carryforwards of $113.3 million and foreign NOL carryforwards of $65.7 million, with expiration dates beginning in 2028 and 2034 respectively [348]. - The company may face limitations on the use of NOL carryforwards due to potential changes in corporate ownership, which could increase future tax liabilities [349]. - The company has never paid dividends on its capital stock and does not anticipate doing so in the foreseeable future, intending to retain earnings for business growth [357]. - Quarterly operating results may fluctuate significantly due to various factors, including reimbursement rates and market conditions, which could impact stock price [358]. Competition and Market Dynamics - The company faces competition in the genomic testing market, particularly for its Decipher Prostate test, from firms like Myriad Genetics and MDx Health [260]. - In the MRD space, the primary competition is from Natera, Inc., with additional competition from companies like Guardant Health, Exact Sciences, and others [263]. - The company is exposed to financial risks related to longer payment cycles and difficulties in collecting from payers in international markets [296]. Innovation and Research - The company is investing in research and development to enhance test offerings, but challenges in obtaining sufficient samples for validation may arise [281]. - The company must continuously innovate to keep pace with rapid technological advancements in diagnostics, or risk obsolescence [284]. - The introduction of new tests necessitates the addition of new billing codes, and failure to implement these changes effectively could harm revenue collection [274]. Legal and Intellectual Property Risks - The company may face infringement claims from competitors, which could result in significant costs and hinder its ability to commercialize products [341]. - The company may incur substantial costs and management distraction from litigation related to its intellectual property rights, which could adversely affect its business [334]. - The company licenses third-party technology, and any inability to secure these licenses on reasonable terms could negatively impact its revenue and margins [337]. - Confidential information may be compromised during intellectual property litigation, potentially impacting investor perception and stock price [345]. Cybersecurity and Data Privacy - Cybersecurity risks are heightened due to complex cyberattack methods, which could compromise sensitive information and disrupt operations [303][304]. - Compliance with evolving data privacy laws, such as GDPR and CCPA, may increase operational costs and potential liabilities [307][313]. - The company must navigate international data transfer restrictions, which could complicate service delivery and increase compliance costs [314]. - The C2i Acquisition involves personal data subject to various privacy laws, increasing compliance complexity and potential liabilities [316][317]. Macroeconomic and Environmental Risks - The company is subject to risks from unfavorable macroeconomic conditions, including inflation and geopolitical challenges, which could adversely impact business operations [363]. - The company’s operations are at risk from disruptions caused by pandemics, political events, and natural disasters, which could affect supply and demand for products [366]. - The company performs genomic testing in regions prone to seismic activity and wildfires, posing additional operational risks [367]. - The company maintains insurance for property damage and business disruption, but this may not cover all potential losses or remain available on acceptable terms [368].

Core Insights - Veracyte, Inc. (VCYT) reported fourth-quarter 2025 adjusted earnings of 53 cents per share, a 47.2% increase year-over-year, exceeding the Zacks Consensus Estimate by 30.06% [1] - The company's GAAP earnings per share were 52 cents, compared to 7 cents in the same period last year [1] - For the full year 2025, EPS reached $1.78, marking a 49.6% increase from the previous year and surpassing estimates by 6.2% [1] Revenue Performance - Revenues for Q4 2025 increased by 18.5% year-over-year to $140.6 million, beating the Zacks Consensus Estimate by 1.4% [2] - Total revenues for 2025 were reported at $517.1 million, a 16% increase from the prior year, also surpassing estimates by 0.4% [2] - Following the earnings announcement, VCYT shares rose by 1.9% in after-hours trading [2] Segmental Revenue Breakdown - Testing revenues reached $135.8 million, up 21.1% year-over-year, driven by growth in Decipher and Afirma revenues of 27% and 16%, respectively [3] - Total testing volume was approximately 45,500, reflecting a 16% increase compared to the prior year [3] - Product revenues increased by 27% year-over-year to $3 million in Q4 [3] Margin Analysis - Total cost of revenues was $36 million, a decrease of 3% year-over-year [5] - Gross profit rose by 28.3% to $104.7 million, with gross margin expanding by 568 basis points to 74.4% [5] - Selling and marketing expenses increased by 4.5% to $25.9 million, while general and administrative expenses decreased by 35.5% to $17 million [5] Cash and Capital Structure - Veracyte ended Q4 2025 with cash and cash equivalents of $362.6 million, up from $239.1 million at the end of 2024 [6] - Cumulative net cash from operating activities was $136.3 million, compared to $75.1 million a year ago [6] Future Guidance - The company reiterated its 2026 revenue guidance of $570 million to $582 million, indicating a growth of 10-13%, with testing revenues expected to grow by 14-16% [8] - The adjusted EBITDA margin is projected to be 25% for 2026 [8] Overall Performance Assessment - Veracyte's fourth-quarter performance showed earnings and revenues exceeding estimates, supported by strong growth in the core testing business [9] - The company has seen a steady pipeline of account wins in Affirma and increased utilization per account, continuing into Q4 [9] - The transition of all Afirma volume to a more scalable, lower-cost platform and record growth in Decipher orders are positive indicators for future performance [10]

Core Insights - Veracyte, Inc. is a leading company in the cancer diagnostics field, specializing in advanced genomic tests for cancer diagnosis and treatment, with notable product lines like Decipher and Afirma [1] Financial Performance - On February 25, 2026, Veracyte reported an earnings per share (EPS) of $0.50, exceeding the estimated EPS of $0.40, indicating effective management and higher profit generation [2][6] - The company's revenue reached approximately $140.6 million, surpassing the anticipated $135.8 million, highlighting the growth of its Decipher and Afirma product lines [2][6] Market Position and Growth - In the last quarter of 2025, Veracyte served over 45,000 patients with its core testing services, demonstrating its ability to expand market presence and deliver valuable diagnostic solutions [3] - The company has a price-to-earnings (P/E) ratio of approximately 42.62, reflecting market confidence in its earnings potential [4] Financial Health - Veracyte has a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing, and a strong current ratio of 8.15, suggesting robust liquidity [5] - The enterprise value to sales ratio is around 4.84, and the enterprise value to operating cash flow ratio is approximately 18.35, providing a comprehensive view of its valuation relative to sales and cash flow [4]

Core Viewpoint - Veracyte reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company achieved earnings of $0.53 per share, surpassing the Zacks Consensus Estimate of $0.41 per share, and up from $0.36 per share a year ago, representing an earnings surprise of +30.06% [1]. - Revenues for the quarter reached $140.64 million, exceeding the Zacks Consensus Estimate by 1.41% and up from $118.63 million in the same quarter last year [2]. Market Performance - Veracyte shares have declined approximately 15.2% since the beginning of the year, while the S&P 500 has gained 0.7% [3]. - The company's stock is currently rated Zacks Rank 2 (Buy), indicating expectations of outperforming the market in the near future [6]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $0.34, with projected revenues of $131.36 million, and for the current fiscal year, the EPS estimate is $1.61 on revenues of $577.29 million [7]. - The Medical - Instruments industry, to which Veracyte belongs, is currently ranked in the top 30% of over 250 Zacks industries, suggesting a favorable outlook for the sector [8].

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, while Afirma grew 12%, contributing to a total testing volume growth of 16% [5][25] - Testing revenue during Q4 was $135.8 million, an increase of 21% year-over-year, with Decipher and Afirma revenue growth of 27% and 16%, respectively [25][26] - Approximately 18,250 Afirma tests were delivered in Q4, representing 12% volume growth, while Decipher tests reached approximately 27,200, marking 15 consecutive quarters of over 20% year-over-year volume growth [9][11] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are still not utilizing the test [12][52] - The bladder cancer segment is currently a small portion of Decipher's total volume, but there is potential for increased use as clinical evidence develops [80] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit revenue growth, supported by a strong pipeline and operational efficiencies [7][24] - The company is focused on building clinical evidence and expanding its market presence, particularly in advanced disease settings [15][19] - Management highlighted the importance of investing in growth drivers while maintaining profitability [28][46] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents, providing flexibility for future investments [25][28] Q&A Session Summary Question: Guidance and Assumptions for 2026 - Management reiterated strong conviction in the 2026 guidance, with factors influencing the high and low ends of the range discussed [32][34] Question: Market Expansion for Prosigna - The potential market for Prosigna is significant, with 225,000 patients annually expected to be addressed by the indication [40] Question: Competitive Dynamics in Decipher Market - Management noted no significant changes in competitive dynamics, with Decipher continuing to show strong growth supported by clinical evidence [52][54] Question: Capital Allocation Strategy - The company maintains a deliberate approach to capital allocation, focusing on organic growth and infrastructure development [69][70]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth, driven by a 21% growth in the core testing business [5][25] - Full year total revenue reached $517 million, achieving 16% growth, with nearly 170,000 patients provided clinically actionable information [6][28] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [7][28] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11][12] - Afirma delivered approximately 18,250 tests in Q4, representing a 12% volume growth, with a market share of approximately 38% [9][10] - Total testing volume for the quarter was approximately 48,000 tests, a 16% increase over the same period in 2024 [25] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder gaining traction [18][80] - The prostate cancer market penetration for Decipher is approximately 33%, indicating significant room for growth [12][52] Company Strategy and Development Direction - The company plans to launch two major products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [8][24] - The company aims to sustain double-digit growth through its portfolio of tests in prostate, thyroid, bladder, and breast cancer [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong financial profile and ongoing investments in growth drivers [28][30] - The company is optimistic about the upcoming product launches and their potential to drive revenue growth [23][30] - Management highlighted the importance of generating clinical evidence to support product adoption and market penetration [16][47] Other Important Information - The company completed the transition of Afirma to a more scalable, lower-cost v2 transcriptome platform, improving operational efficiency [7][10] - The company has a strong cash position, ending the quarter with $412.9 million in cash and cash equivalents [25][28] Q&A Session Summary Question: Has the conviction in the guidance evolved in any way? - Management reiterated strong conviction in the guidance, with expectations for seasonal trends impacting Q1 performance [32][34] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes patients with up to nine nodes, and the results will determine future market expansion [40][41] Question: Can you discuss the competitive dynamics for Decipher? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its market position [52][54]

Financial Data and Key Metrics Changes - Fourth quarter total revenue was $141 million, representing a 19% year-over-year growth driven by a strong core testing business which grew 21% [4] - Full year total revenue reached $517 million, achieving 16% growth [5] - Adjusted EBITDA margin exceeded 27% in 2025, surpassing the 25% target more than a year ahead of plan [6][29] - Cash from operations for Q4 was $52.6 million, ending the quarter with $412.9 million in cash and cash equivalents [26] Business Line Data and Key Metrics Changes - Decipher volume grew 21% in Q4, with approximately 27,200 tests delivered, marking the 15th consecutive quarter of over 20% year-over-year volume growth [11] - Afirma delivered approximately 18,250 tests in Q4, representing 12% volume growth [9] - Total testing volume for Q4 was approximately 48,000 tests, a 16% increase over the same period in 2024 [26] Market Data and Key Metrics Changes - Decipher is recognized as the only gene expression test with high-quality evidence in NCCN guidelines, contributing to its growth [12] - The market penetration for Decipher is approximately 33%, indicating significant room for growth as two-thirds of patients are not yet utilizing the test [53] - The bladder cancer market is transitioning towards more biologically informed evaluations, with Decipher Bladder being integrated into studies to guide treatment decisions [17][85] Company Strategy and Development Direction - The company plans to launch two new products in 2026: TruMRD for muscle-invasive bladder cancer and Prosigna for early-stage breast cancer [8][21] - A phased expansion strategy is in place, focusing on core business momentum and new product launches [7] - The company aims to sustain double-digit growth through its portfolio of tests across prostate, thyroid, bladder, and breast cancer [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining double-digit growth, supported by a strong pipeline and ongoing clinical evidence generation [25][32] - The company is prepared to invest in growth drivers while maintaining profitability, with a focus on clinical evidence and product launches [46][49] - Management highlighted the importance of navigating evolving market dynamics and maintaining a strong operational model [24] Other Important Information - The company achieved significant milestones in 2025, including the launch of Decipher for metastatic patients and the transition of Afirma to a more scalable platform [5][6] - The company is on track to test its 1 millionth patient later this year, reflecting the scale and impact of its platform [5] Q&A Session Summary Question: Has your conviction in the guidance evolved in any way? - Management reiterated strong conviction in guidance, noting seasonal trends and potential drivers for high and low ends of the range [34][35] Question: What readout is required for the OPTIMA study to expand the intended use population? - Management indicated that the OPTIMA study includes enrollment criteria that could allow for expansion, pending positive results [40][42] Question: Can you walk through the push and pulls regarding the margin guidance for 2026? - Management explained that the guidance reflects the need for flexibility to invest in new product launches while maintaining profitability [45][49] Question: How is the competitive landscape for Decipher evolving? - Management noted that Decipher continues to grow despite competition, with strong evidence supporting its use in clinical guidelines [53][55] Question: What is the expected volume growth for Afirma and Decipher in 2026? - Management indicated that Afirma is expected to grow in the mid to high single digits, while Decipher is projected to grow approximately 20% [30][90]

Q4 & FY 2025 Earnings Presentation February 25, 2026 © 2026 Veracyte, Inc. All rights reserved. 1 Forward-looking statements and non-GAAP information This presentation contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, and expectations (financial and otherwise), including with respect to our 2025 and 2026 financial and operating results; our assumptions for future revenue growth; plans and timing of the release of version 2 of our Veracyte tra ...